LivaNova PLC (NASDAQ:LIVN) Holdings Decreased by Kingdon Capital Management L.L.C.

Kingdon Capital Management L.L.C. lessened its stake in LivaNova PLC (NASDAQ:LIVNFree Report) by 10.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 121,000 shares of the company’s stock after selling 13,700 shares during the period. Kingdon Capital Management L.L.C. owned 0.22% of LivaNova worth $6,261,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Headlands Technologies LLC raised its stake in shares of LivaNova by 33.3% in the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after buying an additional 451 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in LivaNova in the third quarter worth about $217,000. Teza Capital Management LLC acquired a new stake in LivaNova in the 3rd quarter valued at about $275,000. Aigen Investment Management LP bought a new position in shares of LivaNova during the 4th quarter valued at about $286,000. Finally, WINTON GROUP Ltd acquired a new position in shares of LivaNova in the 3rd quarter worth approximately $327,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN stock traded up $0.27 on Monday, reaching $52.95. 593,969 shares of the company were exchanged, compared to its average volume of 637,205. The firm has a market capitalization of $2.87 billion, a PE ratio of -88.25 and a beta of 0.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71. The stock’s fifty day moving average price is $57.74 and its 200 day moving average price is $53.66. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47.

LivaNova (NASDAQ:LIVNGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. The firm had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The business’s revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.43 EPS. On average, research analysts anticipate that LivaNova PLC will post 2.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LIVN. Mizuho boosted their target price on LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird upped their price objective on shares of LivaNova from $58.00 to $66.00 and gave the company a “neutral” rating in a research note on Thursday, May 2nd. Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research report on Thursday, June 6th. Barclays boosted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus price target of $66.20.

Check Out Our Latest Report on LivaNova

Insider Activity at LivaNova

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $60.11, for a total transaction of $3,403,608.53. Following the completion of the sale, the director now owns 27,534 shares in the company, valued at $1,655,068.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.27% of the stock is currently owned by company insiders.

LivaNova Profile

(Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.